Drug Profile
Paclitaxel - Qrono
Alternative Names: Paclitaxel Qx; QR 207Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Qrono
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Cancer in USA (Parenteral, Injection)
- 16 Aug 2017 Chemical structure information added
- 03 Aug 2017 Paclitaxel- Qrono is available for licensing as of 03 Aug 2017. http://qrono.com/pipeline/ (Qrono pipeline, August 2017)